Organon & Co.

OGNintermediary

Organon is a women's health-focused pharmaceutical company spun off from Merck in 2021, combining contraceptive and fertility products with a growing biosimilars portfolio.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($6.3B)

靜態數據（加載即時財務…）

Women's Health (28%)

Biosimilars (18%)

Established Brands (54%)

業務部門構成與主要客戶

產品詳情

Nexplanon25%

Long-acting reversible contraceptive implant — #1 in its class

Fertility (Follistim, Ganirelix)15%

Hormone therapies for assisted reproduction

Biosimilars20%

Renflexis, Hadlima, and other biosimilar products

Established Brands40%

Legacy Merck products including Zetia, Nasonex, Cozaar

供應鏈關係

合作夥伴

Merck & Co.

Spun off from Merck in 2021

影響: Medium — legacy Merck product rights

競爭對手

Viatris Inc.

Biosimilar market

影響: Medium — competing biosimilar portfolios

主要客戶

Walgreens Boots Alliance

Pharmacy retail distribution

影響: Low — indirect distribution

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Organon & Co. 的 AI 供應鏈分析。

企業資訊

總部

Jersey City, New Jersey, USA

成立時間

2021

員工人數

10,000+

官網

organon.com

行業概況 — 제약 / 바이오

行業新聞